News Archive

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2014 Archives

Nov 12, 2014
--Webcast and conference call today at 8:30 a.m. EDT--
Nov 5, 2014
Oct 29, 2014
Sep 23, 2014
The Company will hold a conference call today at 5:00 p.m. EDT
Sep 11, 2014
Sep 4, 2014
Two poster presentations from Category 1 abuse-deterrence studies support Egalet-001 abuse-deterrent characteristics
Aug 18, 2014
Plan to initiate pivotal trials in first quarter of 2015 and submit NDA in first half of 2016
Aug 12, 2014
--Webcast and conference call today at 8:30 a.m. EDT--
Aug 6, 2014
--The Company will hold a conference call today at 8:00 a.m. EDT--
Jul 30, 2014
Jul 29, 2014
Jul 28, 2014
Jul 15, 2014
Study showed Egalet-001 has strong abuse-deterrent characteristics including resistance to one of the most common routes of morphine abuse, intravenous injection
May 22, 2014
May 13, 2014
--Webcast and conference call today at 8:30 a.m. EDT--
Apr 29, 2014
Apr 23, 2014
Apr 2, 2014
Apr 1, 2014
Mar 31, 2014
Study showed Egalet-001, extended-release, oral morphine, resistant to common methods of physical manipulation
Mar 26, 2014
-- Strengthened balance sheet with $73.0 million in aggregate gross proceeds from IPO and simultaneous private placement with Shionogi --
Mar 25, 2014
Mar 13, 2014
Mar 11, 2014
Mar 10, 2014
 

 

 

CAREERS

Find out more about opportunities with Zyla Life Sciences.

Career Contact
careers@zyla.com

QUICK LINKS

Sign up for Zyla Life Sciences email alerts.

Investor Contact
ir@zyla.com
Media Contact
media@zyla.com

ZYLA LIFE SCIENCES

U.S. Operations
600 Lee Road, Suite 100
Wayne, PA 19087
Tel: 610.833.4200

© Copyright 2019 Zyla Life Sciences
All rights reserved.